Vés al contingut

Jeremy Lehmann - Genome Editing Screening


CRISPR revolutionized gene editing, but multi-target screening remains a complex goal.  In addition, the fast pace of CRISPR technology development has brought sophisticated options for library screens including new delivery methods for CRISPR gene knockout and the possibility of epigenetic target gene activation.  In this talk, we will explore delivery of CRISPR as both lentivirus and RNP, for gene knockout and activation, in projects ranging in size from use of small gene panels to whole genome pools and arrayed libraries.


Date: Tuesday, 19 June, 2018
Time: 10:30  –  12:30
Place: Dolors Aleu Auditorium, Parc Cientific de Barcelona (PCB)


Jeremy Lehmann

Jeremy has a strong background in genome editing with 10 years of experience in the industry. 9 years have been with Sigma-Aldrich, 6 of them spent working a research and development scientist.  In this role, he first worked with human and mouse ES and IPS cells creating genome edited knock-in cell models and generating reporter cell lines. More recent R&D work has been in the ADME/Toxicology field developing genetically modified primary cells for use in cell based assays for the pharmaceutical industry. He specializes in new product development, gRNA design, donor design, and genotyping screening assay design in his current role as a CRISPR product manager.